The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
This type of tracking helps a practice understand how radiologists interact with AI, whether they're appropriately rejecting incorrect results, and if the technology is improving detection of important findings.
Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's FDA 510(k)-pending photon-counting CT scanner.
Intravascular lithotripsy is expected to see even wider adoption when lower-profile catheters are introduced and device costs start to drop, explained Samin Sharma, MD.
"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.
Artificial intelligence's role in day-to-day patient care continues to grow. What should health systems and cardiology departments be thinking about as they shop for new technologies?
Competition was once fierce between interventional cardiologists and cardiac surgeons, but that has changed over the years. "It is absolutely a partnership," one veteran surgeon told Cardiovascular Business.
Karen Joynt Maddox, MD, MPH, explained the many ways cardiology's business models are starting to evolve. She also touched on a number of other topics, including AI and the power of prevention.
Efforts to expand the scope of practice for these lesser-trained clinicians are increasing as the growing shortage of physicians becomes more pronounced, especially in rural areas.
Alan Matsumoto, MD, chair of the American College of Radiology, explains ACR support for the Radiology Outpatient Ordering Transmission (ROOT) Act in Congress.
